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We developed an in vitro contact through-feet blood brain barrier (BBB) model built using type IV collagen, rat astrocytes, and
human umbilical vein endothelial cells (HUVECs) cocultured through Transwell porous polycarbonate membrane. The contact
between astrocytes and HUVECs was demonstrated by electron microscopy: astrocytes endfeet pass through the 8.0 𝜇m pores
inducing HUVECs to assume a cerebral phenotype. Using this model we evaluated transmigration of melanoma cells from two
different patients (M1 and M2) selected among seven melanoma primary cultures. M2 cells showed a statistically significant
higher capability to pass across the in vitro BBB model, compared to M1. Expression of adhesion molecules was evaluated by
flow cytometry: a statistically significant increased expression of MCAM, 𝛼v𝛽3, and CD49b was detected in M1. PCR array data
showed that M2 had a higher expression of several matrix metalloproteinase proteins (MMPs) compared to M1. Specifically, data
suggest that MMP2 andMMP9 could be directly involved in BBB permeability and that brain invasion by melanoma cells could be
related to the overexpression of manyMMPs. Future studies will be necessary to deepen the mechanisms of central nervous system
invasion.
1. Introduction
Brain metastasis is the most common type of central nervous
system (CNS) tumors being 10-fold more frequent compared
to primary brain tumor [1, 2]. Cerebral metastasis appears
in 30–40% of patients affected by systemic tumors [3] and
the most common derive from lung cancer (17–39%), breast
cancer (5–17%), and melanoma (8–11%) [4].
Melanoma has one of the highest CNSmetastatic capabil-
ity [5, 6] possibly due to the common embryological origin of
melanocytes and neuronal subpopulations [7, 8]. Melanoma
metastases have been shown to have a high mutation rate [9],
variable phenotype, a clinically diffuse dissemination pattern
[10], and the unique ability to elicit spontaneous antigen-
specific host immune responses [11].
Brain is considered a privileged site for the presence of
blood brain barrier (BBB) protecting it against the entry of
toxic substances and microorganisms [12, 13]. Since the CNS
also lacks the lymphatic system, the only way of metastatic
cells to reach the brain is to cross this barrier [14, 15].
BBB is composed by endothelial cells (ECs), sheathing
by astrocytic foot processes, and pericytes. Brain endothelial
cells are anatomically different from the other endothelial
cells and are characterized by the presence of tight junctions
(TJ) and by the absence of fenestrations. Nevertheless the
presence of BBB is not able to prevent parenchymal brain
invasion from different tumor circulating cells and it is sur-
prising that some cancer types give metastases preferentially
to the brain [14]. This phenomenon draws the attention to
the possibility that the BBB may have a supportive role in
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the formation of the metastasis as well: cerebral endothelial
cells have been described to actively take part in the tumor
cells transmigration process. Besides, giving protection to
CNS-invading cells from the immune response and from
chemotherapy, BBB may produce substances favorable for
metastasis growth [16]. The vasculature of the BBB is unique
because of its association with astrocytes: in the brain,
astrocytes and endothelial cells are closely apposed, separated
only by a thin basal lamina [17]; therefore, model involving
physical contact between endothelial cells and astrocytes
more closely represent the in vivo situation [18–20].
Adhesion and junction molecules involved in tumor cell-
endothelial cell interaction are poorly known and even less is
known about brain endothelial-specific mechanisms. Many
authors suggest that tumor cells are able to partly mimic the
molecular mechanisms of leukocyte-endothelial interaction
occurring during inflammation. Depending on this, a role
for integrins and adhesion molecules has been proposed to
explain brain invasion [21, 22].
Indeed, the crossing of the BBB has been described
to involve several mechanisms among which adhesion
molecules, extracellular degradation molecules, and growth
factors [14, 21–24]. Using an in vitro heterologous BBBmodel
[14] in the present work we investigated which of these
was predominant in melanoma to brain metastasization.
Transmigration of melanoma cells from different patients
was evaluated to identify and characterize cell cultures with
different behaviour. Due to the features of the model, we
focused our attention on adhesion [21–23] and extracellular
matrix degradation processes [24].
2. Materials and Methods
2.1. Cell Cultures. HUVECs primary cultures were isolated
from healthy donors according to Jaffe method [25] and used
in experiments up to the tenth passage. The typical purity
of cells cultures was higher than 95% as assessed by flow
cytometry after CD31 staining (polyclonal phycoerythrin-
conjugated goat anti-humanCD31, BDBioscience).HUVECs
were cultured in complete EBM (Endothelial Basal Medium,
Lonza, Walkersville MD) medium completed with growth
factors and antibiotics (EGM SingleQuots, Lonza) in cells
culture dishes (Corning, USA) coated with Collagen S type
I, 0.3 𝜇g/mL (Roche, Mannheim, Germany).
Rat astrocytes cells were commercially available primary
cultures (rat brain cortex, Cambrex lot number 151104AT2)
and were used in experiments up to the tenth passage.
Cells were cultured in 75 cm2 flasks (Corning) in DMEM
(Dulbecco’s Modified Eagle’s Medium, Gibco) completed
with 10% of foetal bovine serum (FBS, Gibco) and antibi-
otics penicillin/streptomycin 1% (P/S, Gibco). Purity of cells
cultures was tested by flow cytometry using an alexa fluor-
conjugate antiglial fibrillary acid protein (GFAP) antibody;
cells were used in experiments when the percentage of GFAP
reached at least 95%.
Primary cultures of melanoma metastases were devel-
oped from surgical specimens as previously described [26]
and were kindly provided by Dr. Licia Rivoltini (National
Cancer Institute of Milan). Cells were cultured in 75 cm2
flasks (Corning) in RPMI (Gibco), in addition to10% FBS
(Gibco) and P/S 1% (Gibco).
2.2. Establishment of the In Vitro BBB Model. In vitro BBB
model was built with rat astrocytes and HUVECs cocultured
through Transwell porous polycarbonate 8𝜇m membrane
(inner well), in 24 well plates (outer well) (Corning). The day
before the preparation of the BBB model, the polycarbonate
membrane was coated with 100 𝜇L of collagen IV at a concen-
tration of 33 𝜇g/mL (mouse collagen, IV, BD Biosciences) for
1 h at room temperature (RT), then washed three times with
phosphate buffered saline (PBS) without CaCl
2
and MgCl
2
(Gibco), and incubated in complete medium (100 𝜇L in the
inner well and 600 𝜇L in the outer well) for 24 hours at 37∘C
in humidified atmosphere with 5% CO
2
. Astrocytes (200.000
cells) were seeded on the bottom side of the polycarbonate
membrane insert, upside-down in humidified chamber for
1 hour. After that, the Transwell insert was inverted in a
24 well cell culture cluster (Costar, Corning Incorporated)
in DMEM complete medium and placed over night at 37∘C
in humidified atmosphere with 5% CO
2
. After 24 hours,
HUVECs (200.000 cells) were plated on the upper side of
polycarbonate membrane and cultured in EBM complete
medium. Astrocytes and HUVECs were than cocultured in
EBM complete medium for four days before being used in
transmigration experiments.
2.3. Trans-Endothelial Flux of L-Glucose. To assess the
integrity of the in vitro BBB model, permeability of the
barrier to L-glucose was tested as previously described [27].
Briefly, a solution of PBS with HEPES 20mM containing
[14C]-L-glucose 1 𝜇M (0.2 𝜇Ci/𝜇L, Amersham Biosciences)
was prepared. Medium was removed from both inner and
outer well of the Transwell and the outer well was filled with
600𝜇L of PBS containing HEPES 20mM, while the inner
well was filled with 100 𝜇L of the solution containing [14C]-
L-glucose. 10 𝜇L aliquots of the inner and outer well solution
were removed at 10 minutes intervals for 1 hours, spotted
onto glass fibre filters (Filtermat A, Wallac) and air-dried for
2 hours at room temperature. Glass fibre filters were than
absorbed in liquid scintillation (Beta Plate Scint 1250-440)
and counted (Trilux 1450 MicroBeta, Wallac).
2.4. Immunocytochemistry. After four days of coculture,
Transwell inserts with HUVECs and astrocytes were fixed for
immunocytochemical evaluation of representative markers
of the BBB tight junctions, zonula occludens-1 (ZO-1) and
vinculin. For ZO-1 detection inserts were fixedwith a solution
of paraformaldehyde-lysine-periodate (PLP) [28] in 0.1M
phosphate buffer, pH 7.4 (PB) for 20min, while for vinculin
detection paraformaldehyde 4% in PBS was used. After
washes with PBS, a pretreatment for antigen unmasking
was performed with a solution of 0.5% Triton X-100 in
50mM MES pH 6, 3mM EGTA, and 5mM MgCl
2
, for
5min, followed by washes with PBS and incubation with
PBS containing 1% bovine serum albumin for 30min. The
following primary antibodies were incubated overnight at
4∘C: ZO-1 (1 : 400, Zymed Lab., San Francisco, CA) and vin-
culin (1 : 400, Sigma, St. Louis, MO). In order to distinguish
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endothelial cells from astrocytes in the insert, double staining
with biotinylated lectin from Lycopersicon esculentum (bLEA,
Sigma Aldrich, St. Luis, MO), specific for endothelial cell
glycocalyx residui (N-acetyl-D-glucosamine oligomers) [29,
30] was carried out. After washes with PBS, secondary
antibodies were incubated for 1 hour at room temperature: for
ZO-1 goat anti-rabbit DyLight TM 488 labeled (1 : 200, KPL,
Gaithersburg, USA), for vinculin goat anti-mouse DyLight
TM 488 labeled (1 : 200, Thermo Scientific, Rockford, USA),
for bLEA Streptavidin Alexa Fluor 594 conjugated (1 : 200,
Life Technologies, Eugene, USA). Negative controls, without
the primary antibody, were also stained each run. Finally,
nuclei were counterstained using DAPI 100 𝜇g/mL (Sigma-
Aldrich) and a solution of PBS and Glycerol (1 : 2, Merck,
Darmstadt, Germany) was added. Inserts were observed and
analysed by Nikon D Eclipse C1 confocal laser-scanning
microscope (Nikon, Tokyo, Japan).
2.5. Electron Microscopy (EM). We checked for the pres-
ence of two crucial ultrastructural markers: the presence of
HUVECs and astrocytes as a single layer, and the presence
of tight junctions (sites of apparent fusion between two
adjacent cells formed by the two opposite membranes and
characterized by electron-dense material). After four days of
coculture, specific polycarbonate membranes were removed
from the inserts and specimens were fixed in 2,5% EM
grade glutaraldehyde (Fluka Chemie, AG Buchs CH) in
0.05Mphosphate buffer (PB) pH 7.4, postfixed in 1% osmium
tetroxide (EMS, Fort Washington, PA, USA) in 0.05M PB,
dehydrated in graded acetone and embedded in Spurr epoxy
resin (EMS, Fort Washington PA USA). Thin sections 1𝜇m
thick were counterstained with toluidine blue and observed
under optic microscope. Ultrathin sections (500 A˚ thick)
of selected areas including HUVECs/astrocytes monolayers
were harvested on 200mesh copper grids (EMS), stainedwith
uranyl acetate and lead citrate, and viewed under an electron
microscope (Zeiss EM 109, Germany).
2.6. Transmigration Assay. Subconfluent cultured melanoma
cells were harvested, washed in PBS, and labelled with the
fluorescent tracer 5-6-carboxyfluorescein diacetate, succin-
imidyl ester (5(6)-CFDA, SE; CFSE) followingmanufacturer’s
instruction (Invitrogen, Italy). After CFDA labelling, cells
were washed with PBS (with CaCl
2
e MgCl
2
), centrifuged,
and resuspended in complete medium (RPMI 10% FBS) at a
concentration of 100.000 cells/100𝜇L. 100 𝜇L of this solution
were added to the inner well of the Transwell in which the
in vitro BBB was established as previously described and
incubated at 37∘C. After 24 hours, transmigrated cells were
collected in the outer well of the Transwell and counted by
fluorescence microscopy using a Fuchs-Rosenthal chamber.
Data regarding transmigrated cells are expressed as per-
centage of the total number of melanoma cells used. As
controls, in any transmigration experiment, migration of
melanoma cells through the polycarbonate membrane alone
was also included. To confirm the presence of the endothelial
and astrocytic monolayer, in each experimental session, one
polycarbonate insert used in a transmigration experiment
was processed for ultrastructural evaluation. Specimens were
treated and viewed as described above; melanoma cells
were identified by the presence of melanosomes in their
cytoplasms.
2.7. Expression of Adhesion Molecules. HUVECs and
melanoma cells were analysed by flow cytometry to evaluate
the expression of the following surface proteins: ICAM-1,
ICAM-2, VCAM-1, MCAM, 𝛼v𝛽3, CD-49b, CD56(NCAM),
and CCR7. Cells were labelled with the following fluorescein-
5-isothiocyanate- (FITC-) or phycoerythrin- (PE-) conju-
gated antibody: ICAM-1/PE (Caltag Laboratories, cat. num-
ber 322708), ICAM-2/FITC (Alexis Corporation), VCAM-1/
PE (BD Pharmingen, cat. number 555647), MCAM/PE
(Beckman Coulter cat. number PN A07483), 𝛼v𝛽3/FITC
(Millipore, cat. number MAB1976F), CD49b/PE (eBiosci-
ence, cat. number 11-0498-41), CD56(NCAM)/FITC (cat.
number 345811 BD Biosciences), and CCR7/FITC (eBiosci-
ence cat. number 11-1979-71).
Briefly, subconfluent cells were harvested with
trypsin/EDTA (Gibco) and incubated with 1 𝜇g of each
antibody at 4∘C for 1 hour. Cells were washed ones with
PBS, acquired using a FacsVantage SE (Becton Dickinson,
CA, USA) and analysed by CellQuest Pro software (Becton
Dickinson). Data are expressed as ratio between the mean
fluorescence intensity (MFI) of the specific antibody and the
MFI of the relative isotypic control (Simultest, 𝛾1/𝛾2a, Becton
Dikinson, USA). MFI ratio values greater than 1 indicate
expression of the molecule on the cell surface.
2.8. Real Time PCR. Total RNA was isolated by RNeasy Mini
Kit (Qiagen, Milano, Italy) following manufacturer’s instruc-
tions and quantified by NanoDrop 2000 Spectrophotometer
(Thermo Scientific, Wilmington, USA). Equal amounts of
RNA of each sample were reverse transcribed using RT2
First Strand Kit (Qiagen, Italy). The expression of 84 differ-
ent tumor-related genes was conducted by Human Tumor
Metastasis RT2 Profiler PCR Array (Qiagen, Italy) using RT2
SYBR Green ROX qPCRMaster Mix and 100 ng of total RNA
for each reaction, following the manufacturer’s protocol. Ct
values obtained were normalised to the Ct value of 𝛽-actin,
the most conserved housekeeping gene present in the array
(ΔCt) and ΔΔCt was calculate as ΔCtM2 − ΔCtM1. Data are
expressed as fold change (2−ΔΔCt) in M2 compared to M1. To
validate the results of the tumor metastasis array, changes in
the expression of selected genes (MCAM, PLAUR, VEGFA,
SYK, and HPSE) was confirmed by single Taqman assays
(Applied Biosystems, Germany) on two different biological
replicates.
3. Results
3.1. In Vitro BBB Model. We developed an in vitro BBB
model which is a “contact through-feet” model. It is built
with human endothelial cells deriving from HUVECs and
rat astrocytes cocultured in Transwell 8.0 𝜇m porous poly-
carbonate membrane (see Materials and Methods for further
details).We obtained amodel that satisfied some of the in vivo
BBB characteristics; by electronmicroscopywe demonstrated
that our model allowed astrocytes endfeet to physically
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Figure 1: (a)The endothelial cells (E) were plated on the upper side of polycarbonate membrane at a density of 2 ⋅ 105/well and the astrocytes
(A) were cultured on the bottom side of the membrane at a density of 2 ⋅105/well.The arrowhead shows the contact between astrocyte endfeet
and endothelial cells monolayer across a pore (P) of the membrane. (b) Contact (arrowhead) between astrocyte endfeet (A) and endothelial
cells (E) across a pore (P) at higher magnification. (c) Transversal section of endothelial cells monolayer (E) after four days of cocultures with
astrocytes (see Material and Methods). Arrows indicate the tight junction (TJ) between two adjacent endothelial cells.
contact HUVECs through membrane pores (Figure 1(a))
inducing the formation of tight junctions (Figure 1(b)) which
is a morphological feature indicating the acquisition of
functional properties of the cerebral endothelium.
To investigate the “tightness” of this model, we evaluated
the permeability of our in vitro BBB to [14C]-L-glucose
[27]. We measured radioactivity content in the medium of
HUVECs cocultured with astrocytes and of HUVECs or
polycarbonate inserts alone sampling medium at 10 minutes
intervals for 1 hour.The ratio between radioactivitymeasured
in the lower chamber and the radioactivity measured in
the upper chamber of the Transwell showed that L-glucose
permeability was strongly reduced by the presence of the
monolayer of HUVECs alone and even more reduced when
HUVECs were cocultured with astrocytes (Figure 2). The
comparison between in vitro BBB and the HUVECs mono-
layer alone showed a statistically significant reduction in
permeability as early as 10 minutes after the addition of
[14C]-L-glucose in the upper chamber. In the insert with
polycarbonate membrane alone, the equilibrium was almost
reached after 60 minutes (Figure 2).
The model was further characterised analysing the
expression of zonula occludens-1(ZO-1) and vinculin
(Figure 3). The immunoreactivity for ZO-1 was localized at
the boundaries of endothelial cells. Labelling for vinculin
showed a slightly different pattern, mainly distributed as a
diffuse cytoplasmic band at endothelial cell periphery and
around the nucleus.
3.2. Transmigration Assay. The ability of 7 metastatic mela-
noma primary cultures to transmigrate across our in vitro
barrier model was screened in preliminary experiments to
estimate if they had different ability to transpass the BBB
model (data not shown).
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Figure 2: Graphic representation of [14C]L-glucose permeability
assay in our in vitro BBB model (see Material and Methods).
A statistically significant decrease to L-glucose permeability was
detected in cocultures after four days (-◊-) if compared to poly-
carbonate membrane alone (-󳵳-) or to HUVEC alone (-◻-) plated
on the upper side of the polycarbonate membrane for four days.
[14C]L-Glucose permeability was expressed as ratio between the
radioactivity measured in the lower chamber and the radioactivity
measured in the upper chamber of the Transwell. A ratio of 1 means
complete equilibrium between the upper and the lower well of the
Transwell. Data are expressed as mean values ± SD (error bars) from
at least three independent experiments. Statistics: in vitroBBBversus
HUVEC alone (𝑡-test).
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Figure 3: The panel shows the localization of two markers representative of the blood brain barrier tight junctions. (a) Expression of zonula
occludens-1 (ZO-1) focalized in membrane producing a linear staining at cell boundaries and (b) merge of ZO-1 and nuclear staining (10x
magnification); (B) magnification detail of ZO-1 andDAPI staining (40xmagnification); (c) membrane-cytoskeletal protein of focal adhesion
plaques vinculin protein; and (d) merge of vinculin and nuclear staining (10x magnification); (D) magnification detail of vinculin and DAPI
staining (40x magnification). DAPI: blue; ZO-1: green; vinculin: green. Scale bar: 100 𝜇m.
Among the various primary cultures analyzed, two
(named M1 and M2) were selected for more detailed analysis
based on their different capability to transmigrate across the
in vitro BBBmodel.TheM2 cell culture showed a statistically
significant higher capability to cross the in vitro BBB model
when compared to M1 (Figure 4(a)). As a matter of fact, M1
showed a mean percentage of migrated cells of 0.038% while
M2 showed a mean value of 0.13% (𝑃 = 0.000016, Student’s
𝑡-test).
To excludemajor differences in genericmotility of the two
primary cultures in our experimental model, transmigration
ability across the polycarbonate membrane alone was also
measured and no differences were detected (Figure 4(b)).
These data suggest that the presence of the in vitro BBB
is actually responsible of the observed differences in cells
transmigration among the two cell lines.
Since the experimental model forces cells to pass through
8 𝜇m pores, we assumed the cell volume as a relevant
parameter in our assay. We therefore measured the cellular
volume using flow cytometry; forward scatter was measured
for both cell lines and results are reported in Figure 5. No
statistically significant differences were detected in cellular
volume between M1 and M2 cells.
3.3. Expression of Metastasis-Related Molecules. To investi-
gate putative molecular mechanisms responsible for the dif-
ferent transmigration behaviour observed in M1 and M2, we
analyzed the expression of some proteins potentially involved
in adhesion and transmigration process like integrins and
adhesion molecules by cytofluorometry: CD49b, ICAM1,
MCAM, CD56, 𝛼v𝛽3, VCAM1, ICAM2, and CCR7 were
analysed and the data obtained are summarized in Figure 5.
A statistically different expression was detected for 𝛼v𝛽3,
CD49b, and MCAM, which were more expressed in M1
compared to M2 cells (Figures 6(a) and 6(b); 𝑃 < 0.05,
Student’s 𝑡-test). On the other hand, a trend to decreased
expression of ICAM-1 and CD56 was detected in M1 cells
even if no statistically significant differences were found
(Figure 6(a)).
To identify differentially expressed genes possibly con-
tributing to the increased ability of M2 cells to cross the in
vitro BBB, mRNA expression of 84 genes involved in tumor
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Figure 4: (a) Transmigration of M1 and M2 cells across the HUVECs monolayer cocultered with astrocytes (in vitro BBB). 100.000 cells
were added in the upper chamber and, after 24 hours, transmigrated cells were counted in the lower chamber (see Material end Methods).
Transmigrated cells are expressed as percentage of the total number of melanoma cells used for each insert. Data are expressed as mean ±
SD (error bars) from at least six independent experiments. M2 cells showed a statistically significant increased migration compared to M1
(∗𝑃 = 0.000016, t-test). (b) Transmigration ability through the polycarbonate membrane alone was similar in M1 and M2 cells. 100.000 cells
were loaded in the upper well of the Transwell chamber and incubated for 24 h. Data are expressed as mean percentage of the total number
of cells ± SD (error bars) from at least six independent experiments.
metastasization was screened using a specific real time PCR-
based array that allowed amplification of different groups of
transcripts (see Material and Methods). The array enabled us
to analyze different tumor metastasis-related genes involved
in cell adhesion, cell cycle, cell growth and proliferation,
apoptosis, extracellular matrix protein, transcription factors,
and regulators.
Data obtained underwent statistical evaluation and only
genes that were expressed less or more than twofold
(2−ΔΔCt) were considered, respectively, downregulated or
upregulated in the M2 cells which displayed the highest
transmigration ability in our in vitro model. A complete
list of the results obtained is reported in Supplementary
Table 1 (see Supplementary Material available online at
http://dx.doi.org/10.1155/2015/476069). Since migration of
melanoma cells was measured after 24 hours, we assumed
as marginal the effects of proliferation in our experimental
conditions and in Tables 1(a) and 1(b) are summarised the
results concerning regulation of adhesion molecules (AM)
and extracellular degradation molecules (EMD) genes.
3.4. Downregulated Genes. Ten out of the 14 downregu-
lated genes (71.5%) encoded for adhesion molecules (AM)
while 28.5% encoded for extracellular matrix degradation
molecules (EMD). SYK, a tyrosine kinase widely expressed in
hematopoietic cells, displayed the highest decrease (−91.72)
followed by melanoma cell adhesion molecule (MCAM)
(Table 1(a)).
3.5. Upregulated Genes. Genes encoding for molecules
involved in cell growth/proliferation (CG/P) were the most
represented in the group of upregulated genes (54.8% see
supplementary Table 1); however, genes involved in the
synthesis of adhesion molecules and matrix degradation
molecules are shown in Table 1(b).
4. Discussion
CNS metastasis is rather common among patients with
melanoma and there is a growing interest in the development
of in vitro BBB models to better understand the molecular
mechanism of invasion of the CNS by malignant tumor cells.
Several previous studies have underlined the importance
of both astrocytes and endothelial cells to reproduce in vitro
structural and functional characteristics of the BBB in vivo
[16, 31–36]. Since glial factors are well conserved among
species, many heterologous models have been described so
far [37–40].
The pivotal role of astrocytes in maintaining cerebral
homeostasis, participating in neural signal transduction and
transporting nutrients from the circulation to the neurons
and buffering ionic imbalance, has been underlined by a
number of authors [41–44]; in the present studywe developed
an in vitro contact through-feet BBBmodel built with human
noncerebral endothelial cells and rat astrocytes.
The isolation of human cerebral endothelial cells is still
a rare option; therefore in vitro models have been often
developed with extracerebral human endothelial cells forced
to assume a cerebral phenotype by the contact with astro-
cytic endfeet or by astrocyte-conditioned culture media [18,
20, 45–47]. In our experimental conditions, the ability of
astrocytic endfeet to take contact with HUVECs is clearly
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Table 1: Differentially expressed genes inM1 andM2 cells as obtained by the metastasis specific real time PCR-based array (see materials and
methods, Section 2). Data are expressed as fold decrease (a) or increase (b) in M2 compared to M1.
Symbol Gene name Fold Function
(a)
SYK Spleen tyrosine kinase −91.72 AM
MCAM Melanoma cell adhesion molecule −29.76 AM
VEGFA Vascular endothelial growth factor A −7.85 AM
CTNNA1 Catenin (cadherin-associated protein), alpha 1 −6.51 AM
ITGB3 Integrin, beta 3 −6.46 AM
FAT1 FAT atypical cadherin 1 −5.36 AM
HPSE Heparanase −5.05 EMD
CD44 CD44 molecule −5.05 AM
TIMP2 Metallopeptidase inhibitor 2 −4.72 EMD
COL4A2 Collagen, type IV, alpha 2 −4.60 EMD
APC Adenomatous polyposis coli −4.02 AM
PNN pinin Desmosome associated protein −3.53 AM
MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) −2.58 EMD
MTSS1 Metastasis suppressor 1 −2.57 AM
(b)
CDH1 Cadherin 1, type 1, E-cadherin 533 AM
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) 54.35 EMD
ITGA7 Integrin, alpha 7 15.54 AM
CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) 8.23 AM
MMP10 Matrix metallopeptidase 10 (stromelysin 2) 6.83 EMD
TIMP3 TIMP metallopeptidase inhibitor 3 4.92 EMD
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 3.97 AM
MMP9 matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) 3.58 EMD
MMP11 Matrix metallopeptidase 11 (stromelysin 3) 3.55 EMD
MMP13 Matrix metallopeptidase 13 (collagenase 3) 3.31 EMD
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) 2.61 EMD
MGAT5 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 2.22 AM
FN1 Fibronectin 1 2.08 AM
CTSL1 Cathepsin L 2.06 EMD
Forward scatter (FSC)
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Figure 5: To exclude major differences in cell volume between
M1 and M2 cells eventually accounting for the different ability to
transmigrate, the forward scatter of M1 (black bar) and M2 (grey
bar) cell was measured by flow cytometry. Despite M2 showing a
statistically significant increasedmigration through the in vitro BBB
compared to M1, their volume was slightly higher than that of M1
(310 versus 250 arbitrary unit) suggesting that cell volume was not
responsible for the differences observed in transmigration.
demonstrated by electron microscopy. Indeed, the HUVECs
monolayer displayed tight junctions further supporting the
idea that in coculture models noncerebral endothelial cells
may be induced to assume features typical of the cerebral
endothelium [18–20, 20–22].The tightness of our in vitroBBB
model was further supported by the significant decrease in
[14C]-L-glucose permeability detected when both HUVECs
and astrocytes were in coculture, in agreement with previ-
ously reported data about permeability of the BBB to [14C]-
L-glucose, sucrose, or drugs [27, 48–50].
Transmigration data showed that in our model the per-
centage of cells crossing the in vitro BBB model was less
than 0.2%. This is in line with previously published data in
similar models [51, 52]. As a further control, we have tested
the migration of A375 (a commercially available melanoma
cell line) in our model and we found similar transmigration
ability if compared to what was previously reported by other
authors for the same cell line in a similar in vitromodel (data
not shown) [53]. However, also in vivo studies have shown
that less than 0.1% of the cells survive more than 24 h after
injection contributing to the concept that metastasization is
an inefficient process [54].
In our experimental conditions, M1 and M2 cell migra-
tion was similar when tested through the sole polycarbonate
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Figure 6: Surface adhesion molecules expression in M1 (black bars) and M2 cells (grey bars). Cultured cells were stained with the
fluorochrome-conjugated specific antibody for the listed molecules and analyzed by flow cytometry (see Material and Method). Data are
expressed as means ± SD (error bars) of the ratio between the mean fluorescence intensity (MFI) of specific antibody and the MFI of the
relative isotypic control. Values greater than 1 indicate expression of the marker (see Material and Methods). Data refers to at least three
independent experiments. Statistics: M1 versus M2 (𝑡-test): ◻𝑃 = 0.019; ∗𝑃 = 0.0003; 󳵳𝑃 = 0.00005.
membrane and was statistically different only if HUVECs
and astrocytes where present in the model (Figure 3). Taken
together, these findings suggest that the different behaviour
of the two cell cultures was induced by the presence of the
barrier, further supporting that in vitro BBBmodels might be
useful to study CNS-specific migration.
Since the mean volume of M1 and M2 cells was similar, it
seems that in our model the cell size was not a limiting event
in transmigration. This observation further suggests that
the different migratory behaviour depended on the in vitro
barrier described rather than intrinsic differences between
the two cell lines. However, arrest of tumour cells in vivo
was found to take place at the level of capillaries where the
diameter of the vessels is similar to those of the metastatic
cells suggesting a key role for the cell size in early phases of
metastasis formation [55, 56]. Although in vitromodelsmight
be used in the study of themolecularmechanisms involved in
the crossing of the BBB, they can hardly be used in elucidating
all the complex phases of the metastatic process [14].
Surprisingly, our findings showed a general decrease in
the expression of adhesion molecules in the melanoma pri-
mary cell culture displaying the higher in vitromigration rate.
In fact, this decrease was significant for CD49b, NCAM, and
alfaVbeta3 integrin in flow cytometry experiments and was
confirmed by the reduced level of expression detected by real
time PCR of these and of other adhesion molecules (Table 1).
The expression of beta3 integrin has been recently analyzed
by Berghoff el al. [57] in a study on autopsy specimens which
also included melanoma metastasis; beta3 integrin score was
reported to be generally low in all metastasis and very low
or absent in melanoma metastasis. Our observations are in
agreement with these data and would support a negative role
for beta3 integrin in CNS metastatization.
On the other hand, in contrast with several evidences sup-
porting a role for MCAM overexpression in metastatic trans-
formation of various types of tumors including melanoma
[58] prostate cancer [59] and non-small-cell lung carcinoma
[60], our data would suggest that a reduced expression
of MCAM promotes migration. This hypothesis is also in
contrast with previously published data which clearly showed
a role for MCAM in cell motility in melanoma [61]. However,
in our experimental conditions, we could not detect a
statistically significant difference in the migration of the two
cell lines through the sole polycarbonate membrane. Since
MCAMwas expressed on both cell lines, albeit at much lower
level in M2, its role in our model might be marginal.
The increased ability to cross the in vitro BBB detected in
M2 cells compared to M1 correlated with the higher expres-
sion of some of MMPs in this cell line. MMPs are primarily
involved in extra cellular matrix degradation; however, the
literature data also showed their complex role in creating and
maintaining the appropriate microenvironment for tumor
growth at primary and metastatic sites [62]. A role for MMPs
in BBB disruption has been previously reported; indeed,
Fazakas et al. showed that melanoma cells can metastasize to
the brain disrupting the continuity of tight junctions by pro-
ducing proteases and that protease protease inhibitor might
significantly reduce the number of extravasating melanoma
cells [63]. Although in a different cellular model, our results
are in agreement with previously reported data showing that
MMP2 and MMP9 are directly involved in TJs disruption
[64–66]. Moreover they suggest that other MMPs (MMP7,
MMP10, MMP11, and MMP13) might be implicated in CNS
invasion by metastatic melanoma cells.
Due to the restricted accessibility to the CNS to
chemotherapeutics, the prevention of the formation of a brain
BioMed Research International 9
metastasis is of crucial importance; therefore the understand-
ing of the mechanism involved in this complex process is a
key step in developing new therapeutic options.
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